Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 31;10:1808. doi: 10.3389/fimmu.2019.01808

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Solimani, Pollmann, Schmidt, Schmidt, Zheng, Savai, Mühlenbein, Pickert, Eubel, Möbs, Eming and Hertl.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Clinical and immunological response to treatment with the anti-IL-17 monoclonal antibody, secukinumab, in mucocutaneous lichen planus (LP). (A) Clinical appearance of three LP patients before (week 0; W0) and on treatment (W8, W12) with secukinumab. Patients 1 and 2 presented with muco-cutanous lesions while patient three had a recalcitrant LP of the oral mucosa unresponsive to systemic immunosuppressive treatment. Blockade of IL-17A led to a shift from erythematous inflammatory to hyperpigmented post-inflammatory skin lesions and an almost complete disappearance of the mucosal lesions by W12. Clinical course was assessed by the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) showing a marked decrease of cutaneous lesions (ABSIS Skin), mucosal lesions (ABSIS Mucosa I), and substantial improvement of the patients' ability to eat defined foods of increasing consistency without pain and/or bleeding (ABSIS Mucosa II). (B) Immunohistochemical analysis of the inflammatory skin infiltrate before (W0) and after 12 weeks (W12) of treatment (representative images of patient 1 are shown). Markers as below: CD3/CD4/CD8 (liquid permanent red), T-bet/GATA3/IL-17 (3,3′ diaminobenzide brown). The dermal, band-like CD4⁺ and CD8⁺ T cellular infiltrate was strongly reduced at W12 of secukinumab treatment compared to W0. Of note, blockade of IL-17A led to a marked decrease of both IL-17A⁺ and CD4⁺/T-bet⁺ (Th1) cells in the LP lesions (see Figure S1 in the supplement for description of image quantification). (C) Flow cytometric analysis of peripheral blood CD8⁺ and CD4⁺ (defined as CD8⁻) T cells in the three LP patients before (W0) and at W12 of treatment. In contrast to skin lesions, the number of CD3⁺, IFNγ⁺ (Th1), and IL-17A⁺ peripheral blood T cells remained largely unaffected by blockade of IL-17A. Notably, peripheral blood IL-21⁺ T cells were increased in all the three LP patients (see Figure S2 and Table S1 in the supplement for gating strategy and raw data).